Immutep Limited logo
Immutep Limited IMMP
$ 0.29 -5.81%

Annual report 2025
added 04-11-2026

report update icon

Immutep Limited Balance Sheet 2011-2026 | IMMP

Annual Balance Sheet Immutep Limited

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- -17.4 M -8.93 M -16.8 M -6.46 M -15.9 M -5.25 M -14.2 M -22 M -17 M -45.9 M

Long Term Debt

- - - - - 8.79 M 7.64 M 6.65 M 5.78 M 5.03 M - - - - -

Long Term Debt Current

205 K 234 K 185 K 173 K 208 K 129 K - - - - - - - - -

Total Non Current Liabilities

- - - - - - 10.9 M 9.62 M 5.8 M 5.76 M 1.91 M 14.8 K 5.75 K 10.3 K 4.44 K

Total Liabilities

13.3 M 12.1 M 11 M 8.09 M 8.76 M 13.3 M 16.2 M 13.5 M 8.43 M 7.24 M 6.29 M 2.79 M 3.57 M 4.45 M 2.54 M

Deferred Revenue

- - - - - 1.29 M - - - - - - - - -

Retained Earnings

- - - - - -276 M -262 M -245 M -232 M -222 M -160 M -128 M -115 M -99.7 M -79.8 M

Total Assets

157 M 202 M 147 M 102 M 82 M 46.6 M 40.5 M 47 M 35 M 42.6 M 31 M 25.4 M 32.8 M 41.6 M 57.6 M

Cash and Cash Equivalents

67.4 M 162 M 123 M 80 M 60.6 M 26.3 M 16.6 M 23.5 M 12.2 M 20.9 M - - - - -

Book Value

144 M 190 M 136 M 94.1 M 73.3 M 33.3 M 24.4 M 33.5 M 26.5 M 35.3 M 24.7 M 22.6 M 29.2 M 37.2 M 55.1 M

Total Shareholders Equity

- - - - - 33.3 M 24.4 M 33.5 M 26.5 M 35.3 M - - - - -

All numbers in AUD currency

Quarterly Balance Sheet Immutep Limited

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - - - 80.1 K - - - 133 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - 3.42 M - - - 9.93 M - - - 10.9 M - - - 9.62 M - - - 5.8 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - - - 8.76 M - - - 13.3 M - - - 16.2 M - - - 13.5 M - - - 8.43 M - - - 7.24 M - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - - - -275 M - - - -276 M - - - -262 M - - - -245 M - - - -232 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - - - 82 M - - - 46.6 M - - - 40.5 M - - - 47 M - - - 35 M - - - 42.6 M - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - - - 60.6 M - - - 26.3 M - - - 16.6 M - - - 23.5 M - - - 12.2 M - - - 20.9 M - - - 6.76 M - - - - - - - - - - - - - - - - -

Book Value

- - - - - - 73.3 M - - - 33.3 M - - - 24.4 M - - - 33.5 M - - - 26.5 M - - - 35.3 M - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - - - 73.3 M - - - 33.3 M - - - 24.4 M - - - 33.5 M - - - 26.5 M - - - 35.3 M - - - 24.7 M - - - - - - - - - - - - - - - - -

All numbers in AUD currency

Balance Sheet is a fundamental financial report of Immutep Limited, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
BioNTech SE BioNTech SE
BNTX
$ 97.23 1.81 % $ 27.2 B germanyGermany
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 8.47 5.94 % $ 83.7 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.63 -2.42 % $ 8.73 B australiaAustralia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 2.22 2.07 % $ 461 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.78 -4.39 % $ 27.9 M israelIsrael
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Genmab A/S Genmab A/S
GMAB
$ 28.2 -0.18 % $ 18 B danmarkDanmark
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 21.06 3.39 % $ 984 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.35 1.64 % $ 6.83 B spainSpain
GT Biopharma GT Biopharma
GTBP
$ 0.38 2.93 % $ 2.1 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
$ 66.57 -1.85 % $ 7.98 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 28.98 0.31 % $ 1.67 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.44 2.86 % $ 370 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.99 2.4 % $ 4.92 M israelIsrael
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.2 2.82 % $ 449 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.99 -0.93 % $ 3.05 B usaUSA
Immatics N.V. Immatics N.V.
IMTX
$ 10.81 3.64 % $ 680 M germanyGermany
Incyte Corporation Incyte Corporation
INCY
$ 94.08 -2.07 % $ 18.4 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.41 0.51 % $ 2.15 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.47 -1.68 % $ 391 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.48 4.61 % $ 235 M franceFrance
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA